HLA-B27 and other predisposing factors in spondyloarthrapathies

Current Opinion in Rheumatology

Volumn 10, Issue 4, 1998, Pages 282-291

  Khare, Sanjay D ^a   Luthra, Harvinder S ^b   David, Chella S ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B27 ANTIGEN;

BACTERIAL INFECTION; DISEASE PREDISPOSITION; ENTEROBACTERIACEAE; HEREDITY; HISTOCOMPATIBILITY GENE; HLA SYSTEM; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPONDYLOARTHROPATHY; TRANSGENIC MOUSE;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BETA 2-MICROGLOBULIN; DISEASE MODELS, ANIMAL; HLA-B27 ANTIGEN; HUMANS; JOINT DISEASES; SPINAL DISEASES;

EID: 0031664870     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199807000-00002     Document Type: Review

References (73)

1. Woodrow JC: Histocompatibility antigens and rheumatic diseases. Semin Arthritis Rheum 1977, 257-276.
2. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD: Ankylosing spondylitis and HL-A 27. Lancet 1973, i:904-907.
3. Schlosstein L, Terasaki PI, Bluestone R, Pearson CM: High association of an HLA antigen, w27, with ankylosing spondilytis. N Engl J Med 1973, 288:704-706.
4. Khan MA: Epidemiology of HLA-B27 and arthritis. Clin Rheumatol 1996, 15(suppl 1):10-12.
5. Khan MA: An overview of clinical spectrum and heterogeneity of spondyloarthropathies. Rheum Dis Clin North Am 1992, 18:1-10.
6. Geczy AF, Alexander K, Bashir HV, Edmonds JP, Upfold L, Sullivan J: HLA-B27, Klebsiella and ankylosing spondylitis: biological and chemical studies. Immunol Rev 1983, 70:23-50.
7. Smith GW, Blackwell CC, Nuki G: Faecal flora in spondyloarthropathy. Br J Rheumatol 1997, 36:850-854.
8. Coppin HL, McDevitt HO: Absence of polymorphism between HLA-B27 genomic exon sequences isolated from normal donors and ankylosing spondylitis patients J Immunol 1986, 137:2168-2172.
9. 2-microglobulin in transgenic mice [abstract]. Fed Proc 1988, 2:A889.
10. Nickerson CL, Luthra HS, Savarirayan S, David CS: Susceptibility of HLA-B27 transgenic mice to Yersinia enterocolitica infection. Hum Immunol 1990, 28:382-396.
11. Weinreich S, Eulderink F, Capkova J, Pla M, Gaede K, Heesemann J, vanAlphen L, Zurcher C, Hoebe-Hewryk B, Kievits F, Ivanyi P: HLA-B27 as a relative risk factor in ankylosing enthesopathy in transgenic mice. Hum Immunol 1995, 42:103-115.
12. Hammer RE, Maika SD, Richardson JA, Tang J-P, Taurog JD: Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β2m: an animal model of HLA-B27 associated human disorders. Cell 1990, 63:1099-1112.
13. Lahesmaa R, Skumik M, Vaara M, Leirisalo-Repo M, Nissila M, Granfors K: Molecular mimickry between HLA B27 and Yersinia, Salmonella, Shigella and Klebsiella within the same region of HLA alpha 1-helix. Clin Exp Immunol 1991, 86:399-404.
14. Lahesmaa R, Skumik M, Granfors K, Mottonen T, Saario R, Toivanen A, Toivanen P: Molecular mimicry in the pathogenesis of spondyloarthropathies: a critical appraisal of cross-reactivity between microbial antigens and HLA-B27. Br J Rheumatol 1992, 31:221-229.
15. Schwimmbeck PL, Yu DT, Oldstone MB: Autoantibodies to HLA B27 in the sera of HLA B27 patients with spondylitis and Reiter's syndrome: molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease. J Exp Med 1987, 166:173-181.
16. Lahesmaa R, Skurnik M, Toivanen P: Molecular mimicry: any role in the pathogenesis of spondyloarthropathies? Immunol Res 1993, 12:193-208.
17. Scofield RH, Warren WL, Koelsch G, Harley JB: A hypothesis for the HLA-B27 dysregulation in spondyloarthropathy: contribution from enteric organisms, B27 structure, peptides bound by B27, and convergent evolution. Proc Natl Acad Sci U S A 1993, 90:9330-9334.
18. Whelan MA, Archer JR: Chemical reactivity of an HLA-B27 thiol group. Eur J Immunol 1993, 23:3278-3285.
19. Geczy AF, McGuigan LE, Sullivan JS, Edmonds JP: Cytotoxic T lymphocytes against disease-associated determinant(s) in ankylosing spondylitis. J Exp Med 1986, 164:932-937.
20. Benjamin RJ, Madrigal JA, Parham P: Peptide binding to empty HLA-B27 molecules of viable human cells. Nature 1991, 351:74-77.
21. Song R, Harding CV: Roles of proteasomes, transporter for antigen presentation (TAP), and beta 2-microglobulin in the processing of bacterial or particulate antigens via an alternate class I MHC processing pathway. J Immunol 1996, 156:4182-4190.
22. Khare SD, Luthra HS, David CS: Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking β2-microglobulin: a model of human spondyloarthropathies. J Exp Med 1995, 182:1153-1158.
23. Koller BH, Marrack P, Kappler JW, Smithies O: Normal development of mice deficient in beta 2M, MHC class I proteins, and CD8+ T cells. Science 1990, 248:1227-1230.
24. Zijlstra M, Bix M, Simister NE, Loring JM, Raulet DH, Jaenisch R: Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells. Nature 1990, 344:742-746.
25. Glas R, Ohlen C, Hoglund P, Karre K: The CD8+ T cell repertoire in beta 2-microglobulin-deficient mice is biased towards reactivity against self-major histocompatibility class I. J Exp Med 1994, 179:661-672.
26. Cook JR, Solheim JC, Connolly JM, Hansen TH: Induction of peptide-specific CD8+ CTL clones in beta 2-microglobulin-deficient mice J Immunol 1995, 154:47-57.
27. Zugel U, Schoel B, Kaufmann SHE: Beta 2-microglobulin independent presentation of exogenously added foreign peptide and endogenous self-epitope by MHC class I alpha-chain to a cross-reactive CD8+ CTL clone. J Immunol 1994, 153:4070-4080.
28. Lehmann-Grube F, Dralle H, Utermohlen O, Lohler J: MHC class I molecule-restricted presentation of viral antigen in beta 2-microglobulin-deficient mice. J Immunol 1994, 153:595-603.
29. Marks JS, Holt PJ: The natural history of Reiter's disease: 21 years of observations. QJM 1986, 60:685-697.
30. Kennedy LG, Will R, Calin A: Sex ratio in the spondyloarthropathies and its relationship to phenotypic expression, mode of inheritance and age at onset. J Rheumatol 1993, 20:1900-1904.
31. Allen H, Fraser J, Flyer D, Calvin S, Flavell R: Beta 2-microglobulin is not required for cell surface expression of the murine class I histocompatibility antigen H-2Db or of a truncated H-2Db. Proc Natl Acad Sci U S A 1986, 83:7447-7451.
32. Ikeda M, Yamaguchi A, Khare S, David C, Marker Herman E, Yu DTY: HLA-B27 free heavy chains expressed on Beta2M negative cells assume a peptide-presenting conformation. Arthritis Rheum 1996, 39(suppl):S297.
33. Khare SD, Bull MJ, Hansen J, Luthra HS, David CS: Spontaneous disease in HLA-B27 transgenic mice independent of MHC class II molecules: a direct role for B27 heavy chains and not B27 derived peptides. J Immunol 1998, 160:101-106. MHC class II-deficient HLA-B27 transgenic mice developed spontaneous inflammatory disease, ruling out a role of class II molecules in the transgenic mouse model.
34. Parham P: Presentation of HLA class I-derived peptides: potential involvement in allorecognition and HLA-B27-associated arthritis. Immunol Rev 1996, 154:137-154. The author reviews the possibility of presentation of B27-derived peptides by MHC class II molecules in B27-associated diseases.
35. Westman P, Partanen J, Leirisalo-Repo M, Koskimies S: Different DRB1*04 alleles predominate in the Finnish random population and in HLA-B27-positive subpopulations. Tissue Antigens 1994, 44:327-331.
36. Tuokko J, Reijonen H, Ilonen J, Anttila K, Nikkari S, Mottonen T, Yli-Kerttula U, Toivanen A: Increase of HLA-DRB1*0408 and -DQB1*0301 in HLA-B27 positive reactive arthritis. Ann Rheum Dis 1997, 56:37-40.
37. Scofield RH, Kurien B, Gross T, Warren WL, Harley JB: HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. Lancet 1995, 345:1542-1544.
38. Boisgerault F, Tieng V, Stolzenberg M-C, Dulphy N, Khalil I, Tamouza R, Charron D, Toubert A: Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic varients. J Clin Invest 1996, 98:2764-2770.
39. Garcia F, Marina A, Albar JP, Lopez de Castro JA: HLA-B27 presents a peptide from a polymorphic region of its own molecule with homology to proteins from arthritogenic bacteria. Tissue Antigens 1997, 49:23-28.
40. Kalinke U, Arnold B, Hammerling GJ: Strong xenogeneic HLA response in transgenic mice after introducing an alpha 3 domain into HLA B27. Nature 1990, 348:642-644.
41. 2m free heavy-chain-specific HC10 monoclonal antibody and not by [HC + β2m] complex-specific ME1 antibody.
42. Germain RN: MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994, 76:287-299.
43. Cresswell P, Howard JC: Antigen recognition. Curr Opin Immunol 1997, 9:71-74.
44. Barron KS, Reveille JD, Carrington M, Mann DL, Robinson MA: Susceptibility to Reiter's syndrome is associated with alleles of TAP genes. Arthritis Rheum 1995, 38:684-689.
45. Maksymowych WP, Tao S, Li Y, Wing M, Russell AS: Allelic variation at the TAP 1 locus influences disease phenotype in HLA-B27 positive individuals with ankylosing spondylitis. Tissue Antigens 1995, 45:328-332.
46. Westman P, Partanen J, Leirisalo-Repo M, Koskimies S: TAP1 and TAP2 polymorphism in HLA-B27-positive subpopulations: no allelic differences in ankylosing spondylitis and reactive arthritis. Hum Immunol 1995, 44:236-242.
47. Simmons WA, Leong LY, Satumtira N, Butcher GW, Howard JC, Richardson JA, Slaughter CA, Hammer RE, Taurog JD. Rat MHC-linked peptide transporter alleles strongly influence peptide binding by HLA-B27 but not B27-associated inflammatory disease. J Immunol 1996, 156:1661-1667. This study showed a qualitative difference in the endogenous peptides eluted from B27 molecules from two Tap polymorphic rat strains. Both rats strains developed spontaneous inflammatory disease.
48. Van Kaer L, Ashton-Rickardt PG, Ploegh HL, Tonegawa S: TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells. Cell 1992, 71:1205-1214
49. Khare SD, Lee S, Bull MJ, Hanson J, Luthra HS, David CS: Spontaneous inflammatory disease in HLA-B27 transgenic mice does not require endogenous peptide loading: studies with HLA-B27+/Tapo mice [abstract]. Hum Immunol 1997, 55(suppl):5.
50. Madden DR, Gorga JC, Strominger JL, Wiley DC: The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC. Cell 1992, 70:1035-1048.
51. Bjorkman PJ, Saper MA, Samraoui B, Benett WS, Strominger JL, Wiley DC: Structure of the human class I histocompatibility antigen HLA-A2. Nature 1987, 329:506-512.
52. Khan MA: HLA-B27 and its subtypes in world populations. Curr Opin Rheumatol 1995, 7:263-269.
53. Gonzalez-Roces S, Alvarez MV, Gonzalez S, Dieya A, Makni H, Woodfield DG, Housan L, Konenkov V, Abbadi MC, Grunnet N, et al.: HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens 1997, 49:116-123. This article reviews polymorphic amino acid residues in the formation of B27 peptide binding pockets and distribution of B27 alleles in world populations with AS.
54. Rognan D, Scapozza L, Folkers G, Daser A: Rational design of nonnatural peptides as high-affinity ligands for the HLA-B*2705 human leukocyte antigen. Proc Natl Acad Sci U S A 1995, 92:753-757.
55. Weiss GA, Collins EJ, Garboczi DN, Wiley DC, Schriber SL: A tricy ring system replaces the variable regions of peptides presented by alleles of human MHC class I molecules. Chem Biol 1995, 2:401-4.
56. Weiss GA, Valentekovich RJ, Collins EJ, Garboczi DN, Lane WS, Schreiber SL, Wiley DC: Covalent HLA-B27/peptide complex induced by specific recognition of an aziridine mimic of arginine. Proc Natl Acad Sci U S A 1996, 93:10945-10948. At position 2 of the HLA-B27 binding peptide, the authors replaced arginine with an aziridine-containing ligand. This ligand alkylated cysteine at position 67 of the B27 molecule. The authors suggest that the use of such ligands may generate T-cell anergy (if administered alone) or activation (with co-ligands inducing costimulatory signals).
57. Khare SD, Weiss GA, Peterson RT, Lee S, Bull MJ, Hansen J, Schreiber SL, Luthra HS, David CS: A synthetic MHC ligand modulates inflammatory disease in HLA-B27 transgenic mice. Arthritis Rheum 1997, 40(suppl):S330.
58. Zhou M, Maika SD, Simmons WA, Hammer, Taurog JD: Peptide blockade of HLA-B27 affects disease manifestations in transgenic rats. Arthritis Rheum 1997, 40:S172.
59. Rahemtulla A, Fung-Leung WP, Schilham MW, Kundig TM, Sambhara SR, Narendran A, Arabian A, Wakeham A, Paige CJ, Zinkemagel RM, et al.: Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature 1991, 353:180-184.
60. Khalil A, Khare S, Luthra H, David C: HLA-B27 transgenic mice lacking CD4 gene have decreased incidence of spontaneous inflammatory disease. Arthritis Rheum 1997, 40(suppl):S330.
61. Law YM, Yeung RSM, Mamalaki C, Kioussis D, Mak TW, Flavell RA: Human CD4 restores normal T cell development and function in mice deficient in murine CD4. J Exp Med 1994, 179:1233-1242.
62. Fung-Leung WP, Schilham MW, Rahemtulla A, Kundig TM, Vollenweider M, Pottervan J, Ewijk W, Mak TW: CD8 is needed for development of cytotoxic T cells but not helper T cells. Cell 1991, 65:443-449.
63. Madden DR, Gorga JC, Strominger JL, Wiley DC: The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature 1991, 353:321-325.
64. Urben RG, Chicz RM, Lane WS, Strominger JL, Rehm A, Kenter MJH, UytdeHaah FGCM, Ploegh H, Uchanska-Ziegler B, Ziegler A: A subset of HLA-B27 molecules contains peptides much longer than nonamers. Proc Natl Acad Sci U S A 1994, 91:1534-1538.
65. Capps GG, Robinson BE, Lewis KD, Zuniga MC: In vivo dimeric association of class I MHC heavy chains: possible relationship to class I MHC heavy chain-beta 2-microglobulin dissociation. J Immunol 1993, 151:159-169.
66. Gao XM, Wordsworth P, McMichael A: Collagen-specific cytotoxic T lymphocyte responses in patients with ankylosing spondylitis and reactive arthritis. Eur J Immunol 1994, 24:1665-1670.
67. Lee S, Khare SD, Taneja V, Hanson J, Bull M, Griffiths MM, Luthra HS, David CS: HLA-B27+/mouse β2mo/human β2m+ transgenic mice within pathogen-free colony are susceptible to collagen-induced arthritis. Arthritis Rheum 1997, 40(suppl):S260.
68. Khare SD, Luthra HS, David CS: Unraveling the mystery of HLA-B27 association with human spondyloarthropathies using transgenic and knockout mice. Semin Immunol, in press.
69. Rodriguez M, Pedrinaci S, David CS: Human class I major histocompatibility complex transgene prevents virus-induced demyelination in susceptible mutant B10.D2dml mice. Ann Neurol 1993, 33:208-212.
70. McNeil AJ, Yap PL, Gore SM, Brettle RP, McColl M, Wyld R, Davidson S, Weightman R, Richardson AM, Robertson JR: Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. QJM 1996, 89:177-185.
71. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, Goedert JJ, Winkler C, O'Brien SJ, Rinaldo C, et al.: Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996, 2:405-411.
72. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, Giangrande P, Luzzi G, Morgan B, Edwards A, et al.: Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997, 3:212-217.
73. Nelson GW, Kaslow R, Mann DL: Frequency of HLA allele-specific peptide motifs in HIV-1 proteins correlates with the allele's association with relative rates of disease progression after HIV-1 infection. Proc Natl Acad Sci U S A 1997, 94:9802-9807.